Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Paediatr Respir Rev ; 47: 23-26, 2023 Sep.
Article in English | MEDLINE | ID: mdl-37407313

ABSTRACT

We present a challenging case that illustrates how the clinical manifestations in children with CFTR mutations of uncertain significance may change over time. This case highlights the evolution of confirming a diagnosis of CF and emphasises the importance of regular review and monitoring of this patient cohort.


Subject(s)
Cystic Fibrosis , Child , Humans , Infant, Newborn , Cystic Fibrosis/genetics , Cystic Fibrosis/therapy , Cystic Fibrosis/diagnosis , Precision Medicine , Mutation , Neonatal Screening , Cystic Fibrosis Transmembrane Conductance Regulator/genetics
2.
J Cyst Fibros ; 22(3): 538-547, 2023 May.
Article in English | MEDLINE | ID: mdl-37100706

ABSTRACT

BACKGROUND: Cystic fibrosis (CF) disease severity can be highly variable, even between people with CF (pwCF) with similar genotypes. Here we use patient-derived intestinal organoids to study the influence of genetic variation within the cystic fibrosis transmembrane conductance regulator (CFTR) gene on CFTR function. METHODS: Organoids of F508del/class I, F508del/S1251N and pwCF with only one detected CF-causing mutation were cultured. Allele-specific CFTR variation was investigated using targeted locus amplification (TLA), CFTR function was measured using the forskolin-induced swelling assay and mRNA levels were quantified using RT-qPCR. RESULTS: We were able to distinguish CFTR genotypes based on TLA data. Additionally, we observed heterogeneity within genotypes, which we were able to link to CFTR function for S1251N alleles. CONCLUSIONS: Our results indicate that the paired analysis of CFTR intragenic variation and CFTR function can gain insights in the underlying CFTR defect for individuals where the disease phenotype does not match the CFTR mutations detected during diagnosis.


Subject(s)
Cystic Fibrosis Transmembrane Conductance Regulator , Cystic Fibrosis , Humans , Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Cystic Fibrosis/genetics , Intestines , Mutation , Genotype , Organoids
3.
J Cyst Fibros ; 19 Suppl 1: S60-S64, 2020 03.
Article in English | MEDLINE | ID: mdl-31787574

ABSTRACT

Significant progress has been made in the development of CFTR modulator therapy; however, current CFTR modulator therapies are only available for a minority of the CF-patient population. Additionally, heterogeneity in in vivo modulator response has been reported among individuals carrying homozygous F508del-CFTR, adding to the desire for an optimal prediction of response-to-therapy on an individual level. In the last decade, a lot of progress has been made in the development of primary cell cultures into 3D patient-derived disease models. The advantage of these models is that the endogenous CFTR function is affected by the patient's mutation as well as other genetic or environmental factors. In this review we focus on intestinal organoids as in vitro model for CF, enabling for CF disease classification, drug development and treatment optimization in a personalized manner, taking into account rare CFTR mutations and clinical heterogeneity among individuals with CF.


Subject(s)
Cystic Fibrosis , Intestines , Organoids , Patient-Specific Modeling , Primary Cell Culture/methods , Cystic Fibrosis/genetics , Cystic Fibrosis/pathology , Cystic Fibrosis/physiopathology , Cystic Fibrosis/therapy , Humans , In Vitro Techniques , Precision Medicine/methods , Precision Medicine/trends
SELECTION OF CITATIONS
SEARCH DETAIL
...